CELIA KONG: Open Payments
NPI 1982740619 · BEVERLY HILLS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,290 in 59 payments from 11 companies in 2025. Trend: 2023 $431 · 2024 $731 · 2025 $1,290
Food & beverage: $1,215Education: $75
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 13 | $261 |
| ABBVIE INC. | 10 | $208 |
| Janssen Biotech, Inc. | 7 | $178 |
| UCB, Inc. | 10 | $147 |
| GENZYME CORPORATION | 4 | $142 |
| LEO Pharma Inc. | 4 | $89 |
| Botanix SB Inc | 4 | $77 |
| Lilly USA, LLC | 3 | $73 |
| Galderma Laboratories, L.P. | 2 | $64 |
| Incyte Corporation | 1 | $28 |
Products named: TREMFYA, SKYRIZI, Bimzelx, DUPIXENT, COSENTYX, Rhapsido, SOFDRA, ANZUPGO.
Industry payments across CA — which companies pay providers there.
